Evidence map›Paper›PMID 41259014›Full record

ArticleProtein & cell2026

AhR-Siglec-15 axis regulates lysosomal Ca2+ release for sonic hedgehog medulloblastoma growth via TRPML1.

Zhenfeng Wang, Shunshun Li, Xu Sun, Dianheng Wang, Yabo Zhou, Li Zhou, Jie Chen, NanNan Zhou, Qiuying Zhu, Jinyan Liu and 4 more

Abstract read
In one paragraph

Article in Protein & cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhenfeng WangDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.ORCID 0000-0002-7407-7065
Shunshun LiDepartment of Immunology, Basic Medicine College, China Medical University, Shenyang 110122, China.ORCID 0000-0003-3199-5963
Xu SunDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.ORCID 0009-0006-9153-6880
Dianheng WangDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
Yabo ZhouDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
Li ZhouDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
Jie ChenDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
NanNan ZhouDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
Qiuying ZhuDepartment of Clinical Medicine, Yanjing Medical College, Capital Medical University, Beijing 100069, China.
Jinyan LiuBiotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Guihong ZhangDepartment of Pathology, Pathology Center, Anhui Medical University, Hefei 230032, China.
Wei-Min TongDepartment of Pathology, Institute of Basic Medical Sciences, CAMS and Peking Union Medical College, Beijing 100005, China.
Jiadi LvDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.
Bo HuangDepartment of Immunology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College, Beijing 100005, China.ORCID 0000-0001-8476-1138

Funding

Beijing Natural Science Foundation 5254044CAMS Innovation Fund for Medical Sciences 2021-I2M-1-021CAMS Innovation Fund for Medical Sciences 2023-I2M-2-005CAMS Innovation Fund for Medical Sciences 2023-I2M-QJ-008Department of Science & Technology of Liaoning province 2024-BSLH-337National Key Research and Development Program of China 2022YFA1206000National Natural Science Foundation of China 82388201
6 · The paper itself

Abstract

Sonic hedgehog subgroup medulloblastoma (SHH-MB), an aggressive pediatric brain tumor that originates from granule neuron precursors, faces the challenge of poor treatment owing to its unclear molecular mechanisms. Here, we show that sialic acid-binding immunoglobulin-like receptor 15 (Siglec-15), an immunosuppressive membrane protein, is upregulated and mediates SHH-MB growth through its translocation to the lysosomal membrane. We found that SHH-MB cells use the cation-independent mannose 6-phosphate receptor (CI-MPR) to transport Siglec-15 from the trans-Golgi network (TGN) to lysosomes, where Siglec-15 induces lysosomal Ca2+ release by interacting with mucolipin TRP cation channel 1 (TRPML1), leading to the nuclear translocation of the transcription factor EB (TFEB). Blockade of Siglec-15, TRPML1, or TFEB hinders SHH-MB growth in vitro and in vivo. Importantly, aryl hydrocarbon receptor (AhR), a cytoplasmic transcription factor, upregulates Siglec-15 expression. AhR inhibition by CH-223191 or StemRegenin 1 (SR1) achieved therapeutic efficacy against orthotopic SHH-MB xenografts in mice. These findings reveal an essential role for the AhR-Siglec-15 axis in SHH-MB development, providing a potential strategy for SHH-MB treatment.

Indexed as

Basic Helix-Loop-Helix ProteinsCalciumCerebellar NeoplasmsHedgehog ProteinsLysosomesMedulloblastomaReceptors, Aryl HydrocarbonTransient Receptor Potential ChannelsAnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell Line, TumorCell ProliferationHumansMiceAHR protein, humanBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsCalciumHedgehog ProteinsMCOLN1 protein, humanMcoln1 protein, mouseReceptors, Aryl HydrocarbonTransient Receptor Potential ChannelsAhRlysosomeSiglec-15TFEBTRPML1

Identifiers

PMID41259014
PMCPMC13161473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.